Pasithea Therapeutics CorpKTTA
Price$0.49

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$21.3MTTM through 30 Jun 2026
Free Cash Flow -$17.8MTTM through 30 Jun 2026

Margins

Current

Returns

-37.0%ROE
-33.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio11.35x
Net Debt-$55.2Mnet cash position
Cash & Equivalents$45.7M

Quality Metrics

Altman Z-Score2.94
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'21'22
FY2022: $486.6K
Diluted EPS-$1.35TTM
'21'22'23'24'25
FY2025: $-2.91

Dividend

No dividend

Capital Allocation

R&D Spend$10.7M

Segment Performance

SegmentRevenueYoYOutlook
Therapeutics$0
View details

Focusing resources on the clinical development of PAS-004 for neurofibromatosis type 1 (NF1) and other MAPK pathway-driven cancers.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.